This topic contains a solution. Click here to go to the answer

Author Question: What dietary restriction would be anticipated for a client in chronic renal failure who is not on ... (Read 46 times)

mmm

  • Hero Member
  • *****
  • Posts: 558
What dietary restriction would be anticipated for a client in chronic renal failure who is not on dialysis?
 a. sodium less than four grams daily
  b. protein 0.6-0.8 grams per kilogram per day
  c. less than 400 milligrams cholesterol per day
  d. 25 kcalories per kilogram body weight daily

Question 2

A primary cause for calcium leaving the bone in the client in chronic renal failure is:
 a. uremia.
  b. hyperkalemia.
  c. calcium oxalate.
  d. hyperphosphatemia.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

ynlevi

  • Sr. Member
  • ****
  • Posts: 338
Answer to Question 1

b

Answer to Question 2

d




mmm

  • Member
  • Posts: 558
Reply 2 on: Aug 20, 2018
Great answer, keep it coming :)


atrochim

  • Member
  • Posts: 331
Reply 3 on: Yesterday
Thanks for the timely response, appreciate it

 

Did you know?

Calcitonin is a naturally occurring hormone. In women who are at least 5 years beyond menopause, it slows bone loss and increases spinal bone density.

Did you know?

Children with strabismus (crossed eyes) can be treated. They are not able to outgrow this condition on their own, but with help, it can be more easily corrected at a younger age. It is important for infants to have eye examinations as early as possible in their development and then another at age 2 years.

Did you know?

Illicit drug use costs the United States approximately $181 billion every year.

Did you know?

Street names for barbiturates include reds, red devils, yellow jackets, blue heavens, Christmas trees, and rainbows. They are commonly referred to as downers.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library